RU92004344A - SUSTAINABLE MEDICAL FORMS WITH A REGULATED DISTRIBUTION, HAVING ACRYLIC POLYMER COATINGS, AND METHOD OF OBTAINING THEM - Google Patents

SUSTAINABLE MEDICAL FORMS WITH A REGULATED DISTRIBUTION, HAVING ACRYLIC POLYMER COATINGS, AND METHOD OF OBTAINING THEM

Info

Publication number
RU92004344A
RU92004344A RU92004344/14A RU92004344A RU92004344A RU 92004344 A RU92004344 A RU 92004344A RU 92004344/14 A RU92004344/14 A RU 92004344/14A RU 92004344 A RU92004344 A RU 92004344A RU 92004344 A RU92004344 A RU 92004344A
Authority
RU
Russia
Prior art keywords
acrylic polymer
obtaining
polymer coatings
coated
medical forms
Prior art date
Application number
RU92004344/14A
Other languages
Russian (ru)
Other versions
RU2127587C1 (en
Inventor
Бенжамин Ошлак Аи
Марк Чейсин
Франк Педи
Original Assignee
Ороселтик С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/826,084 external-priority patent/US5286493A/en
Application filed by Ороселтик С.А. filed Critical Ороселтик С.А.
Publication of RU92004344A publication Critical patent/RU92004344A/en
Application granted granted Critical
Publication of RU2127587C1 publication Critical patent/RU2127587C1/en

Links

Claims (1)

Устойчивая твердая дозированная лекарственная форма с регулируемым выделением и с покрытием, получаемым из водной дисперсии акрилового полимера, образуется покрытием субстрата, включающего терапевтически активный агент, водной дисперсией пластифицированного акрилового полимера и затем отверждением покрытого субстрата при температуре выше переходной температуры стеклования пластифицированного акрилового полимера до тех пор, пока покрытая дозированная форма не достигнет устойчивой характеристики растворения, на которую не оказывает существенного влияния действие условий хранения при повышенной температуре и/или повышенной относительной влажности.A stable solid dosage form with controlled release and coated with an aqueous dispersion of acrylic polymer is formed by coating a substrate comprising a therapeutically active agent with an aqueous dispersion of plasticized acrylic polymer and then curing the coated substrate at a temperature above the transition glass transition temperature of plasticized acrylic polymer until the coated dosage form reaches a stable dissolution characteristic, which is not The effect of storage conditions at elevated temperature and / or increased relative humidity is of considerable influence.
RU92004344A 1992-01-27 1992-10-19 Stable medicinal forms exhibiting the sustain releasing and having acrylic polymer coatings (variants) and a method of their producing RU2127587C1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/826,084 US5286493A (en) 1992-01-27 1992-01-27 Stabilized controlled release formulations having acrylic polymer coating
US07/826084 1992-01-27

Publications (2)

Publication Number Publication Date
RU92004344A true RU92004344A (en) 1995-02-10
RU2127587C1 RU2127587C1 (en) 1999-03-20

Family

ID=25245664

Family Applications (1)

Application Number Title Priority Date Filing Date
RU92004344A RU2127587C1 (en) 1992-01-27 1992-10-19 Stable medicinal forms exhibiting the sustain releasing and having acrylic polymer coatings (variants) and a method of their producing

Country Status (22)

Country Link
US (1) US5286493A (en)
EP (1) EP0553392B2 (en)
JP (1) JP3957329B2 (en)
AT (1) ATE184786T1 (en)
AU (1) AU660512B2 (en)
BR (1) BR9204577A (en)
CA (1) CA2074309C (en)
DE (1) DE69230028T3 (en)
DK (1) DK0553392T4 (en)
EG (1) EG20307A (en)
ES (1) ES2141713T5 (en)
GR (1) GR3032106T3 (en)
HK (1) HK1005687A1 (en)
HU (1) HU219350B (en)
IL (1) IL102851A (en)
MX (1) MX9205823A (en)
NO (1) NO309360B1 (en)
NZ (1) NZ245298A (en)
PL (1) PL171376B1 (en)
RU (1) RU2127587C1 (en)
SG (1) SG44698A1 (en)
ZA (1) ZA925687B (en)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508371A (en) * 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ Orally administrable therapeutic protein and its production method
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
US5266331A (en) † 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
DE4310012A1 (en) * 1993-03-27 1994-09-29 Roehm Gmbh Dermal therapeutic system made of a meltable poly (meth) acrylate mixture
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) * 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
KR100354702B1 (en) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US6210714B1 (en) 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
DE19531684A1 (en) * 1995-08-29 1997-03-06 Bayer Ag Process for the preparation of controlled release pharmaceutical preparations
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
MX9801835A (en) 1996-07-08 1998-08-30 Mendell Co Inc Edward Sustained release matrix for high-dose insoluble drugs.
JPH1050306A (en) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd Manufacture of hydrogen storage alloy electrode
AU4807197A (en) * 1996-10-03 1998-04-24 Paul Bunn Hydrophilic microparticles and methods to prepare same
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
PT1041987E (en) 1997-12-22 2006-07-31 Euro Celtique Sa PHARMACEUTICAL FORM OF ORAL DOSAGE, UNDERSTANDING A COMBINATION OF AN AGRONIST OF OPIOIDE AND NALTREXONE
JP2001526229A (en) * 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． How to prevent abuse of opioid dosage forms
DE19808634A1 (en) * 1998-02-24 1999-08-26 Schering Ag Production of pharmaceutical pellets, especially containing iloprost, with stabilized release properties
US6471975B1 (en) 1998-05-01 2002-10-29 3M Innovative Properties Company Microspheres as a delivery vehicle for bio-active agents useful in agricultural applications
US7354596B1 (en) 1998-05-01 2008-04-08 3M Innovative Properties Company Anti-microbial agent delivery system
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US7083808B2 (en) * 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
US6673367B1 (en) * 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
FR2794646B1 (en) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques MORPHINE SULFATE MICROGRANULES, METHOD OF PREPARATION AND COMPOSITION CONTAINING THEM
IN191239B (en) 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US7030097B1 (en) * 1999-07-14 2006-04-18 Cornell Research Foundation, Inc. Controlled nucleic acid delivery systems
MXPA02002105A (en) * 1999-08-27 2003-12-11 Southern Res Inst Injectable buprenorphine microparticle compositions and their use.
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (en) 1999-10-29 2011-10-15 Euro Celtique Sa CONTROLLED RELEASE HYDROCODONE FORMULATIONS
IL151058A0 (en) 2000-02-08 2003-04-10 Euro Celtique Sa Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
AU2002306629A1 (en) * 2001-03-02 2002-09-19 Euro-Celtique, S.A. Method and apparatus for compounding individualized dosage forms
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (en) 2001-05-02 2007-12-25 Euro Celtic S A Dosage form of oxycodone and use thereof
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
AU2002314968B2 (en) * 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
ATE419039T1 (en) * 2001-07-18 2009-01-15 Euro Celtique Sa PHARMACEUTICAL COMBINATIONS OF OXYCODONE AND NALOXONE
RU2004106619A (en) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) COMPOSITIONS OF AN OPIOID AGONIST CONTAINING A RELEASABLE AND ISOLATED ANTAGONIST
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003020242A1 (en) * 2001-08-29 2003-03-13 Srl Technologies, Inc. Sustained release preparations
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
WO2004026235A2 (en) * 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
ES2733051T1 (en) 2002-04-05 2019-11-27 Euro Celtique Sa Matrix for sustained, invariable and independent release of active compounds
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
MXPA05001826A (en) 2002-08-15 2005-04-19 Euro Celtique Sa Pharmaceutical compositions.
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20060148877A1 (en) * 2002-11-26 2006-07-06 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
PT2218448E (en) 2002-12-13 2016-01-26 Durect Corp Oral drug delivery system comprising high viscosity liquid carrier materials
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20050048118A1 (en) * 2003-07-25 2005-03-03 Joan Cucala Escoi Modified release venlafaxine hydrochloride tablets
SI1663229T1 (en) 2003-09-25 2010-08-31 Euro Celtique Sa Pharmaceutical combinations of hydrocodone and naltrexone
AU2004275835B2 (en) * 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
MXPA06003454A (en) * 2003-09-26 2006-08-31 Johnson & Johnson Controlled release formulations of opioid and nonopioid analgesics.
KR20060115860A (en) * 2003-09-26 2006-11-10 알자 코포레이션 Oros push-stick for controlled delivery of active agents
EP1708684A2 (en) 2003-09-26 2006-10-11 Alza Corporation Drug coating providing high drug loading and methods for providing the same
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
PT1691811E (en) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050152969A1 (en) * 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
TWI483944B (en) * 2004-03-30 2015-05-11 Euro Celtique Sa Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
LT1765292T (en) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US7776358B2 (en) * 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
DE102004035938A1 (en) * 2004-07-23 2006-02-16 Röhm GmbH & Co. KG Process for the preparation of coated drug forms with stable drug release profile
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
KR20080046751A (en) * 2004-09-01 2008-05-27 유로-셀띠끄 소시에떼 아노님 Opioid dosage forms having dose proportional steady state cave and auc and less than dose proportional single dose cmax
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
ES2675581T3 (en) * 2005-02-25 2018-07-11 Takeda Pharmaceutical Company Limited Method for producing granules of a coated benzimidazole compound
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
FR2883179B1 (en) 2005-03-18 2009-04-17 Ethypharm Sa COATED TABLET
WO2006102603A2 (en) * 2005-03-24 2006-09-28 Medtronic, Inc. Modification of thermoplastic polymers
RU2008113439A (en) * 2005-09-09 2009-10-20 Лабофарм Инк. (CA) COMPOSITIONS WITH SLOW DELIVERY OF A MEDICINAL PRODUCT
FR2894143B1 (en) * 2005-12-01 2008-05-02 Pierre Fabre Medicament Sa PROLONGED RELEASE COMPOSITION OF THE ACTIVE INGREDIENTS, PROCESS FOR PREPARING THE SAME AND USE THEREOF
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
WO2007092718A2 (en) * 2006-02-07 2007-08-16 Fmc Corporation Coating process to produce controlled release coatings
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
KR20150029762A (en) 2006-06-19 2015-03-18 알파마 파머슈티컬스 엘엘씨 Pharmaceutical compositions
EA017832B1 (en) 2006-08-04 2013-03-29 Этифарм Granule and orally disintegrating tablet comprising oxycodone
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
WO2009023672A2 (en) * 2007-08-13 2009-02-19 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
JP2008024708A (en) * 2007-08-20 2008-02-07 Euro-Celtique Sa Controlled release type preparation coated with aqueous dispersion of acrylic polymer and method therefor
PT2057984E (en) 2007-11-09 2010-03-10 Acino Pharma Ag Retard tablets with hydromorphon
EP3326621A1 (en) 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
CN105456267A (en) * 2008-07-07 2016-04-06 欧洲凯尔特公司 Use of opioid antagonists for treating urinary retention
TR201809389T4 (en) 2008-09-25 2018-07-23 Isp Investments Llc Smooth, high solids tablet coating composition.
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8811578B2 (en) * 2009-03-23 2014-08-19 Telemanager Technologies, Inc. System and method for providing local interactive voice response services
DE102009034308A1 (en) * 2009-07-21 2011-02-03 Winkelmann, Wolfgang, Dr. Medical preparation for the treatment of inflammatory processes
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
MX2012012991A (en) 2010-05-11 2012-11-30 Cima Labs Inc Alcoholres i stant metoprolol - containing extended - release oral dosage forms.
CN101987083B (en) * 2010-07-16 2012-12-12 钟术光 Preparation method for controlled release preparation, especial for zero-order release controlled release preparation
CN102018962B (en) * 2010-07-16 2013-11-06 钟术光 Polymer intensifier in controlled release preparation
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
ES2444591T3 (en) 2010-10-28 2014-02-25 Acino Pharma Ag Medication with the active substance hydromorphone with improved storage stability
WO2012080833A2 (en) 2010-12-13 2012-06-21 Purdue Pharma L.P. Controlled release dosage forms
AU2011346757B2 (en) 2010-12-22 2015-08-20 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
JP5638151B2 (en) 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ Tamper resistant solid oral dosage form
JP5146859B2 (en) * 2011-07-11 2013-02-20 ユーロ−セルティーク エス．エイ． Controlled release formulation coated with aqueous dispersion of acrylic polymer and method thereof
ES2716570T3 (en) 2012-04-17 2019-06-13 Purdue Pharma Lp Systems and methods for treating or preventing an adverse pharmacodynamic response induced by opioids
TW201639855A (en) 2012-07-16 2016-11-16 羅德科技公司 Process for improved opioid synthesis
WO2014013313A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9120800B2 (en) 2013-08-02 2015-09-01 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone alkaloid and oxymorphone salts
TWI539952B (en) 2014-01-15 2016-07-01 羅德科技公司 Process for improved oxymorphone synthesis
JP2017502991A (en) 2014-01-15 2017-01-26 ローズ テクノロジーズ Method for improved oxycodone synthesis
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
WO2017015309A1 (en) 2015-07-22 2017-01-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
WO2017049185A1 (en) * 2015-09-17 2017-03-23 Ahmad Syed Taymur Process for protecting an electronic device by selective deposition of polymer coatings
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US20180083662A1 (en) * 2016-09-16 2018-03-22 Syed Taymur Ahmad Process for protecting an electronic device by selective deposition of polymer coatings
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
ES2938608T3 (en) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60166608A (en) * 1984-02-08 1985-08-29 Japan Atom Energy Res Inst Slow-releasing composite having sandwich structure and its preparation
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US5068110A (en) * 1987-09-29 1991-11-26 Warner-Lambert Company Stabilization of enteric coated dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
JP2558396B2 (en) * 1990-06-28 1996-11-27 田辺製薬株式会社 Controlled release formulation
ZA923474B (en) * 1991-05-20 1993-01-27 Marion Merrell Dow Inc Diltiazem formulation

Similar Documents

Publication Publication Date Title
RU92004344A (en) SUSTAINABLE MEDICAL FORMS WITH A REGULATED DISTRIBUTION, HAVING ACRYLIC POLYMER COATINGS, AND METHOD OF OBTAINING THEM
CA2074309A1 (en) Stabilized controlled release formulations having acrylic polymer coating
CA2061824A1 (en) Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
EP1502591A3 (en) Controlled-release formulations coated with aqueous dispersions of ethylcellulose
CA2304110A1 (en) Theophylline sustained release tablet
ATE150963T1 (en) SPHERE-SHAPED GRANULES WITH A CORE AND THEIR PRODUCTION
NO175307C (en) Analogous Process for the Preparation of New Therapeutically Active 3,3'-Dithiobis (Propionic Acids)
NO791750L (en) WATER PLASTIC DISTRIBUTION ON THE BASIS OF VINYLESTER POLYMERS, PROCEDURES FOR THEIR PREPARATION AND FROM THE COATING AGENT
NO160133C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2-AMINO-3- (HALOBENZOYL) -METHYLPHENYLEDIC ACETIC ACIDS, ESTERS AND SALTS THEREOF.
WO1992019209A3 (en) Taste-masked medicaments and their preparation
FR2453640A1 (en) Controlled release of di:hydro-Ergotamine methane sulphonate - from micro-granules coated with anionic and cationic methacrylic! polymers and a plasticiser
Tackett et al. Storage of Grit Blasted Biomedical Components: Affects on Ti--6 Al--4 V Porous Coating Bondstrength